(Reuters) – Pfizer Inc said on Wednesday its experimental treatment for moderately to severely active ulcerative colitis met the main goal of a late-stage study.
Ulcerative colitis is a chronic, inflammatory bowel disease affecting the colon and causing recurrent flares of abdominal pain and bloody diarrhea.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Maju Samuel)
